Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6613536B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1997 |
| Grant date | Sep 2, 2003 |
| Priority date | — |
| Expiry date | Sep 29, 2017 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/104
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Synthetic peptides based on a complementarity-determining region (CDR) of the heavy or light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease in mice, and analogs, and salts and chemical derivatives thereof; dual peptides comprising two such peptides or analogs covalently linked to one another either directly or through a short linking chain; peptide polymers comprising a plurality of sequences of said peptide or analog thereof; and peptide polymers attached to a macromolecular carrier, are disclosed, and pharmaceutical compositions comprising them for the treatment of SLE in humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.